Blog
RSS FeedPosted by Michael Wonder on 02 Apr 2024
Relugolix–estradiol–norethisterone acetate for the treatment of patients with pain associated with endometriosis
28 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 01 Apr 2024
PHARMAC publishes agenda for May 2024 PTAC meeting
28 March 2024 - Another slim agenda; one cancer medicine. ...
Posted by Michael Wonder on 27 Mar 2024
Satralizumab for the prevention of relapse in patients with a neuromyelitis optica spectrum disorder
27 March 2024 - NICE is unable to make a recommendation on the use of satralizumab (Enspryng) for the prevention of ...
Posted by Michael Wonder on 27 Mar 2024
Ritlecitinib tosylate for the treatment of people 12 years and over with alopecia areata
27 March 2024 - NICE has published final evidence-based recommendations on the use of ritlecitinib tosylate (Litfulo) for the treatment ...
Posted by Michael Wonder on 26 Mar 2024
Cost and value of cancer medicines in a single payer public health system in Ontario, Canada: a cross-sectional study
26 March 2024 - We describe temporal trends in expenditure on cancer medicines within the single-payer health system of Ontario, Canada, ...
Posted by Michael Wonder on 21 Mar 2024
Momelotinib dihydrochloride monohydrate for the treatment of patients with myelofibrosis-related splenomegaly or symptoms
20 March 2024 - NICE has published final evidence-based recommendations on momelotinib dihydrochloride monohydrate (Omjjara) for the treatment of aduklts ...
Posted by Michael Wonder on 21 Mar 2024
New leaders for medicines and medical services committees
20 March 2024 - Two esteemed medical experts have been appointed to oversee the committees that advise Government on funding medicines, ...
Posted by Michael Wonder on 19 Mar 2024
Pharmac initiated lengthy review a waste of valuable time and resources, says Rare Disorders NZ
19 March 2024 - Rare Disorders NZ is very concerned that Pharmac will not extend access to life-saving medicines for ...
Posted by Michael Wonder on 18 Mar 2024
Co-design of an enhanced consumer engagement process
18 March 2024 - A consumer-led Co-design Working Group has developed proposed recommendations for enhancing consumer engagement processes to enable ...
Posted by Michael Wonder on 15 Mar 2024
Public Summary Documents (first time rejections and deferrals) – November 2023 PBAC meeting
15 March 2024 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the November 2023 PBAC ...
Posted by Michael Wonder on 14 Mar 2024
Exagamglogene autotemcel for the treatment of patients with sickle cell disease
14 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 13 Mar 2024
Dupilumab for the treatment of adults with moderate to severe prurigo nodularis
13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of ...
Posted by Michael Wonder on 13 Mar 2024
Fluocinolone acetonide for the treatment of patients with chronic diabetic macular oedema
13 March 2024 - NICE has published final evidence-based recommendations on the use of fluocinolone acetonide intravitreal implant (Iluvien) for ...
Posted by Michael Wonder on 12 Mar 2024
Updated agenda for March 2024 PBAC meeting (12 March 2024)
12 March 2024 - There are five late changes to the agenda for this week's PBAC meeting. ...
Posted by Michael Wonder on 12 Mar 2024
SMC - March 2024 decisions
11 March 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...